{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:02:34Z","timestamp":1772114554951,"version":"3.50.1"},"reference-count":76,"publisher":"Baishideng Publishing Group Inc.","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2021,9,28]]},"DOI":"10.3748\/wjg.v27.i36.6039","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:51:25Z","timestamp":1632365485000},"page":"6039-6052","source":"Crossref","is-referenced-by-count":13,"title":["Liver disease in the era of COVID-19: Is the worst yet to come?"],"prefix":"10.3748","volume":"27","author":[{"given":"Ivana","family":"Mikolasevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorotea","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tajana","family":"Pavi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Ruzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Radic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfa","family":"Radic-Kristo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanija","family":"Razov-Radas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeljko","family":"Puljiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Milic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2020.06.006"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2566"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14730"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14601"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30190-4"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i19.2323"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.036"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.021"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13338"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00029-7"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.05.001"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321553"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31281"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100113"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0328-2"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6913e2"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.035"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31301"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00018"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.002"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14435"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30057-1"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.006"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.001"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14470"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.044"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.027"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15112"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321611"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.09.015"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2020.08.018"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.025"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02734-1"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0387-z"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.10.020"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.04.046"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25806"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31307"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927452"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00053"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14486"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.042"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.013"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1159\/000512152"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.064"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.005"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1159\/000510765"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.007"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2020.05.032"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0347-z"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15933"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15876"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.032"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25756"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.040"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31257"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.616381"},{"key":"B68","unstructured":"U.S. National Library of Medicine.   Identifier NCT00287391. [cited 27 Feb 2021]. In: ClinicalTrials.gov [Internet]. 2000 Feb 29 - . [about 15 screens]. Available from: URL: https:\/\/clinicaltrials.gov\/ct2\/results?cond=liver+disease&Search=Apply&recrs=a&age_v=&gndr=&type=&rslt="},{"key":"B69","unstructured":"Erlandson K, Lake JE.   Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Birmingham (AL): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04216589?recrs=a&cond=liver+disease&draw=3&rank=58 ClinicalTrials.gov Identifier: NCT04216589"},{"key":"B70","unstructured":"Rotman Y.   Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03884075?recrs=a&cond=liver+disease&draw=3&rank=44 ClinicalTrials.gov Identifier: NCT03884075"},{"key":"B71","unstructured":"Cha BS.   Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD \/ SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Seoul: U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03646292?recrs=a&cond=liver+disease&draw=3&rank=47 ClinicalTrials.gov Identifier: NCT03646292"},{"key":"B72","unstructured":"Ahuja K, Sheflin-Findling S.   Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. New Hyde Park (NY): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04671186?recrs=a&cond=liver+disease&draw=3&rank=60 ClinicalTrials.gov Identifier: NCT04671186"},{"key":"B73","unstructured":"Cusi K.   Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Gainesville (FL): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03459079?recrs=a&cond=liver+disease&draw=3&rank=53 ClinicalTrials.gov Identifier: NCT03459079"},{"key":"B74","unstructured":"Kar PS.   Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. New Delhi: U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04594954?recrs=a&cond=liver+disease&draw=3&rank=26 ClinicalTrials.gov Identifier: NCT04594954"},{"key":"B75","unstructured":"Taub R.   A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients (MAESTRO-NAFLD1). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Birmingham (AL): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04197479?recrs=a&cond=liver+disease&draw=3&rank=24 ClinicalTrials.gov Identifier: NCT04197479"},{"key":"B76","unstructured":"CohBar, Inc.   A Phase 1a\/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Chula Vista (CA): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03998514?recrs=a&cond=liver+disease&draw=3 ClinicalTrials.gov Identifier: NCT03998514"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v27\/i36\/6039.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:51:37Z","timestamp":1632365497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v27\/i36\/6039.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":76,"journal-issue":{"issue":"36"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v27.i36.6039","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}